articles with this tag
$2.6M Capped eSense-Lab Signs US$600k Revenue Deal
Jun 19, 2020
Backed by a new leadership team, ASX-listed biotech junior, eSense-Lab (ASX:ESE) is implementing a new business model that sees it enter joint venture (JV) agreements to quickly reach multiple revenue-generating markets.
OSL’s Pancreatic Cancer Treatment Approved for Sale in Europe
May 5, 2020
OncoSil Medical (ASX:OSL) has received CE Mark approval to market and sell its breakthrough implantable radiotherapy treatment for pancreatic cancer in the EU and UK.
ASX MedTech Junior Displays Promise for Pancreatic Cancer Patients
Jan 30, 2020
OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.
ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations
Dec 19, 2019
One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).